Oslo - Delayed Quote NOK

Ultimovacs ASA (ULTI.OL)

Compare
2.5500 -0.1000 (-3.77%)
At close: December 20 at 4:25:17 PM GMT+1
Currency in NOK All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
162,346.0000
215,733.0000
183,629.0000
163,832.0000
124,146.0000
Operating Income
-162,346.0000
-215,733.0000
-183,629.0000
-163,832.0000
-124,146.0000
Net Non Operating Interest Income Expense
320.0000
13,745.0000
8,663.0000
2,729.0000
4,340.0000
Pretax Income
-149,276.0000
-189,239.0000
-167,792.0000
-164,722.0000
-120,552.0000
Net Income Common Stockholders
-149,276.0000
-189,239.0000
-167,792.0000
-164,722.0000
-120,552.0000
Diluted NI Available to Com Stockholders
-149,276.0000
-189,239.0000
-167,792.0000
-164,722.0000
-120,552.0000
Basic EPS
-4.30
-5.50
-4.90
-5.10
-4.00
Diluted EPS
-4.30
-5.50
-4.90
-5.10
-4.00
Basic Average Shares
34,405.5000
34,398.0000
34,247.0000
32,373.0000
30,260.0000
Diluted Average Shares
34,405.5000
34,398.0000
34,247.0000
32,373.0000
30,260.0000
Total Operating Income as Reported
-162,349.0000
-215,736.0000
-183,631.0000
-163,832.0000
-124,146.0000
Rent Expense Supplemental
5,035.0000
4,874.0000
4,221.0000
3,645.0000
2,949.0000
Total Expenses
162,346.0000
215,733.0000
183,629.0000
163,832.0000
124,146.0000
Net Income from Continuing & Discontinued Operation
-149,276.0000
-189,239.0000
-167,792.0000
-164,722.0000
-120,552.0000
Normalized Income
-162,017.0000
-201,980.0000
-172,845.0000
-163,244.0000
-120,552.0000
Interest Income
1,870.0000
14,127.0000
8,906.0000
3,062.0000
4,580.0000
Interest Expense
--
--
--
333.0000
240.0000
Net Interest Income
320.0000
13,745.0000
8,663.0000
2,729.0000
4,340.0000
EBIT
-151,801.0000
-215,733.0000
-183,629.0000
-163,832.0000
-124,146.0000
EBITDA
-149,010.0000
-212,965.0000
-180,981.0000
-161,129.0000
-121,426.0000
Reconciled Depreciation
2,791.0000
2,768.0000
2,648.0000
2,703.0000
2,720.0000
Net Income from Continuing Operation Net Minority Interest
-149,276.0000
-189,239.0000
-167,792.0000
-164,722.0000
-120,552.0000
Total Unusual Items Excluding Goodwill
12,741.0000
12,741.0000
5,053.0000
-1,478.0000
--
Total Unusual Items
12,741.0000
12,741.0000
5,053.0000
-1,478.0000
--
Normalized EBITDA
-161,751.0000
-225,706.0000
-186,034.0000
-159,651.0000
-121,426.0000
12/31/2020 - 6/3/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

LYTIX.OL Lytix Biopharma AS
5.70
+1.79%
 
LIDDS.ST LIDDS AB (publ)
0.1045
-0.95%
 
NANECH.ST NanoEcho AB
0.1580
+21.54%
 
QUIA.ST Quia Pharma AB (publ)
0.0172
+3.61%
 
COMBI.ST CombiGene AB (publ)
2.7200
+5.43%
 
NYKD.OL Nykode Therapeutics AS
2.8880
-3.41%
 
DIABIO.ST Diagonal Bio AB (publ)
0.0258
+5.31%
 
ONCIN.OL Oncoinvent ASA
3.0900
-4.92%
 
PCIB.OL PCI Biotech Holding ASA
1.3200
-7.04%
 
ZICC.ST Ziccum AB (publ)
0.3830
-6.36%